Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

NCT00986414 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease
Dyskinesias

Interventions

DRUG: AFQ056
DRUG: AFQ056
DRUG: AFQ056
DRUG: AFQ056
DRUG: AFQ056
DRUG: Placebo

Sponsor

Novartis